Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study

Short-term outcome after simultaneous pancreas-kidney transplantation with alemtuzumab vs. basiliximab induction: a single-center retrospective study

Abstract During the COVID-19 pandemic our center adjusted the standard induction therapy for normal immunological risk simultaneous pancreas-kidney (SPK) transplantations from T-cell depletion by alemtuzumab (ALEM) to IL-2 receptor blocking by basiliximab (IL2R). Here, we analyze the impact of this...

Full description

Saved in:
Bibliographic Details
Main Authors: Tim D. A. Swaab, Robert A. Pol, Meindert J. Crop, Jan-Stephan F. Sanders, Stefan P. Berger, Hendrik S. Hofker, Stephan J. L. Bakker, Charlotte A. te Velde-Keyzer
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Pancreas transplantation
Immunosuppression
Induction
Alemtuzumab
Basiliximab
COVID-19
Online Access:https://doi.org/10.1038/s41598-025-06750-y
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items